Pharma announces extra data from APF530 Phase 3 research on CINV A.

As previously reported, the Phase 3 study demonstrated APF530 was comparable to palonosetron in avoiding both severe – and delayed-beginning point CINV in patients receiving either moderately emetogenic chemotherapy or extremely emetogenic chemotherapy . Related StoriesOvarian cancer sufferers with a brief history of oral contraceptive use have better outcomesStudy shows rare HER2 missense mutations usually do not spread breasts cancer on the ownMeat-rich diet may increase kidney cancer risk ‘Delayed-onset nausea and vomiting remains a significant issue associated with many cancer treatment options, which can affect a patient’s quality of life as well as his or her capability to sustain the recommended lifesaving chemotherapy regimen potentially,’ said Rebecca A.Furthermore, protections are set up to guard patients personal and health information and to ensure that physicians are accessing and analyzing the correct treatment plan for each patient. ‘At Accuray, we continue steadily to supply our doctors and patients with innovative, cutting-advantage treatment solutions,’ stated Euan S. Thomson, Ph.D., president and ceo of Accuray. ‘The healthcare field is constantly evolving and flexibility is more essential than ever before. With PlanTouch, we are putting the power of the CyberKnife System’s treatment planning technology onto the ipad tablet and in to the hands of treating physicians.